PDL BioPharma (PDLI) Tops Q4 EPS by 7c

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.61, $0.07 better than the analyst estimate of $0.54. Revenue for the quarter came in at $178.1 million versus the consensus estimate of $149.2 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Fastly’s 14% AI spike was a mirage; Here’s the edge stock Citi says you should own
• Moody’s cuts Baidu outlook to negative as AI capital costs weigh on margins